Skip to main content
Thomas Kosten, MD, Psychiatry, Houston, TX

ThomasRichardKostenMD

Psychiatry Houston, TX

Addiction

Director, Division of Alcohol and Addiction Psychiatry, Baylor College of Medicine

Dr. Kosten is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kosten's full profile

Already have an account?

  • Office

    2002 Holcombe Blvd
    Va Bldg 110, Room 229
    Houston, TX 77030
    Phone+1 713-794-7032

Education & Training

  • Yale University
    Yale UniversityM.A., 1995
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Addiction Psychiatry, 1983 - 1983
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Addiction Psychiatry, 1981 - 1983
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Psychiatry, 1978 - 1981
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterInternship, Transitional Year, 1977 - 1978
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1977
  • Rensselaer Polytechnic Institute
    Rensselaer Polytechnic InstituteB.S., Biophysics, 1973

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2007 - 2024
  • CT State Medical License
    CT State Medical License 1979 - 2023
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • Distinguished Life Fellow American Psychiatric Association (APA), 2014
  • Research Career Award American Psychiatric Association (APA), 2011
  • Research Career Award Spanish Psychiatric Association (SPA), 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic  
    Thomas R Kosten, Ismene L Petrakis, JAMA Psychiatry
  • Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury  
    Thomas R Kosten, David P Graham, JAMA
  • Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms  
    An HM, Tan YL, Shi J, Wang ZR, Li J, Wang YC, Lv MH, Zhou DF, Soares JC, Kosten TR, Yang FD, Zhang XY, Behav Brain Res, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • Cocaine and Methamphetamine: Pharmacology to Pipeline Treatments 
    Anaheim, CA - 1/3/2014
  • Vaccines for Addictions 
    Houston, TX - 1/9/2013
  • Ethical Issues Related to Agonist Therapy for Opoid Addictions 
    Houston, TX - 1/9/2013
  • Join now to see all

Other

Authored Content

  • Innovative Non-Opioids for Chronic Pain: Cannabidiol and KetamineOctober 2019
  • Innovative Non-Opioids for Chronic Pain: Cannabidiol and KetamineOctober 2019

Press Mentions

  • Heroin Antibody Fares Better Than Earlier Therapies That Targeted Its Metabolites
    Heroin Antibody Fares Better Than Earlier Therapies That Targeted Its MetabolitesNovember 1st, 2022
  • Exhibition: ‘The Human Cost: America’s Drug Plague’ at the Bronx Documentary Center, New York
    Exhibition: ‘The Human Cost: America’s Drug Plague’ at the Bronx Documentary Center, New YorkJune 13th, 2021
  • $25 Million NIH Grant Funds Adjuvant Opioid Use Disorder Vaccine
    $25 Million NIH Grant Funds Adjuvant Opioid Use Disorder VaccineApril 21st, 2021
  • Join now to see all

Grant Support

  • Multisite Controlled Trial Of Cocaine Vaccine (1of 6) LEAD Site/ Houston TreatmenNational Institute On Drug Abuse2008–2012
  • Human Methamphetamine Vaccine: Translational Avante Garde AwardNational Institute On Drug Abuse2011
  • Stimulant Pharmacotherapy: Noradrenergic TargetsNational Institute On Drug Abuse2009–2011
  • Methadone StudiesNational Institute On Drug Abuse2009–2011
  • Clinical Methods CoreNational Institute On Drug Abuse2009–2011
  • Kappa Opioid Antagonist For Cocaine AddictionNational Institute On Drug Abuse2005–2011
  • Developing Immunotherapeutics For Methamphetamine AbuseNational Institute On Drug Abuse2009–2010
  • Comorbidity In Cocaine And Opioid PharmacotherapyNational Institute On Drug Abuse2006–2010
  • Tropisetron With Risperidone For SchizophreniaNational Institute Of Mental Health2007–2009
  • Administrative And Scientific CoreNational Institute On Drug Abuse2007–2008
  • Cocaine Pharmacotherapy Targeting Dopamine &GabaNational Institute On Drug Abuse2006–2008
  • Pharmacotherapies Of Cocaine Addiction In HumansNational Institute On Drug Abuse2007
  • Heroin Addiction Treatment: Naltrexone And LofexidineNational Institute On Drug Abuse2006–2007
  • Comorbidity In Cocaine And Opioid PharmacotherapyNational Institute On Drug Abuse2005
  • Heroin Addiction Treatment: Naltrexone And LofexidineNational Institute On Drug Abuse2004–2005
  • Cocaine Pharmacotherapy Targeting Dopamine &GabaNational Institute On Drug Abuse2004–2005
  • Scientific And Administrative CoreNational Institute On Drug Abuse2004
  • Cocaine Vaccine For Methadone Maintained PatientsNational Institute On Drug Abuse2002–2004
  • Pharmacotherapy For Opioid And Cocaine DependenceNational Institute On Drug Abuse2001–2004
  • Comorbidity In Cocaine And Opioid PharmacotherapyNational Institute On Drug Abuse2000–2004
  • Cocaine Pharmacotherapies For Comorbid PopulationsNational Institute On Drug Abuse1999–2003
  • FMRI Of Gender And Stress Response In Cocaine DependenceNational Institute On Drug Abuse2002
  • Therapeutic Cocaine VaccineNational Institute On Drug Abuse2000–2002
  • Immunological Agents For Cocaine AbuseNational Institute On Drug Abuse2000–2002
  • Active Immunization To Develop Antibodies To CocaineNational Institute On Drug Abuse2000–2002
  • Core--Medication Development Research CenterNational Institute On Drug Abuse1999–2002
  • Clopidogrel &Isradipine For Brian Perfusion Defects In Cocaine AbusersNational Institute On Drug Abuse1999–2002
  • 11th - 15th Annual Meetings And SymposiaNational Institute On Drug Abuse2000–2001
  • Buprenorphine Maintenance For Opioid AddictsNational Institute On Drug Abuse1988–2000
  • 9th/13th Annual Meeting And SymposiumNational Institute On Drug Abuse1998–1999
  • Clinical Research Center For Opioid And Cocaine AbuseNational Institute On Drug Abuse1991–1999
  • Immunological Agents For Cocaine AbuseNational Institute On Drug Abuse1997–1998
  • Active Immunization To Develop Antibodies To CocaineNational Institute On Drug Abuse1997–1998
  • Core--CoreNational Institute On Drug Abuse1996–1998
  • Yale Medications Development Research CenterNational Institute On Drug Abuse1994–1998
  • Non-Opioid Neurobiology Of Opioid DependenceNational Institute On Drug Abuse1996–1997
  • Cocaine Discrimination In Humans--Effects Of Dopaminergic AgentsNational Institute On Drug Abuse1996–1997
  • Agonist To Antagonist--New ApproachesNational Institute On Drug Abuse1994–1995
  • Reducing AIDS RisksNational Institute On Drug Abuse1994
  • Matching Methadone Patients To Psychosocial TreatmentNational Institute On Drug Abuse1993–1994
  • Small Instrumentation GrantNational Institute On Drug Abuse1993
  • Treatment Research Unit--Reducing AIDS RisksNational Institute On Drug Abuse1989–1993
  • Agonist To Antagonist: New ApproachesNational Institute On Drug Abuse1987–1993
  • The Yale University Substance Abuse Research CenterNational Institute On Drug Abuse1991
  • Pharmacotherapy Of IV Cocaine Use In Methadone PatientsNational Institute On Drug Abuse1987–1989

Professional Memberships

  • American College of Neuropsychopharmacology
    Fellow
  • Distinguished Life Fellow
  • AMERICAN ACADEMY OF ADDICTION PSYCHIATRY
    PAST PRESIDENT & DISTINGUISHED FELLOW
  • College on problems of drug dependence
    Past President and Distinguished Fellow